What did Promisia Healthcare Limited announce?
Promisia Healthcare Limited (NZX: PHL) filed “PHL – Waivers from NZX Listing Rules 7.8.5(b) and 7.8.8(b)” with NZX on 13 August 2026, as a nzx compliance announcement.
- Which company?
- Promisia Healthcare Limited (NZX: PHL)
- When was it filed?
- 13 August 2026
- Where is the original?
- NZX announcement
PHL – Waivers from NZX Listing Rules 7.8.5(b) and 7.8.8(b)
NZ RegCo
0
13 August 2026
NZ RegCo Decision
Promisia Healthcare Limited (PHL)
Application for waivers from NZX Listing Rules 7.8.5(b)
and 7.8.8(b)
NZ RegCo
1
Background
1. The information on which this decision is based is set out in Appendix One to this decision. These
waivers will not apply if that information is not, or ceases to be, full and accurate in all material
respects.
2. The NZX Listing Rules (Rules) to which this decision relates is set out in Appendix Two.
3. Capitalised terms that are not defined in this decision have the meanings given to them in the
Rules.
Waiver from Rule 7.8.5(b) and Rule 7.8.8(b)
Decision
4. Subject to the conditions set out in paragraph 5 below, and on the basis that the information
provided by PHL is complete and accurate in all material respects, NZ RegCo grants PHL a
waiver from Rule 7.8.5(b) and Rule 7.8.8(b) to the extent that these Rules require PHL to
commission an Appraisal Report to accompany its Notice of Meeting for shareholders to consider
a resolution to approve entry into a transaction to:
a. purchase the shares in Chatswood Retirement Limited and Chatswood Lifecare Limited from
vendors that include a Related Party of PHL; and
b. approve an issue of shares to a Related Party of PHL as part of the Purchase Price for the
transaction,
(the Transaction).
5. The waiver in paragraph 4 above is provided on the conditions that:
a. the directors of PHL that are not interested in the Transaction (Non-Interested Directors)
certify to NZ RegCo that in their opinion:
i. the Share issue is in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders;
ii. the Acquisition is in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders;
iii. the terms of the Acquisition have been entered into and negotiated on an arm’s length
commercial basis;
iv. PHL was not influenced enter into the Acquisition by the Related Party; and
v. the waivers are in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders;
with such certificate to fully explain the Non-Interested Directors’ reasons for their opinion;
b. the waiver, its conditions, and implications being disclosed in PHL’s Notice of Meeting;
c. a confirmation letter which sets out the outcome of the independent valuation of Chatswood
as at 31 July 2026 (Independent Valuation) will accompany the Notice of Meeting and
includes:
i. a statement from the independent valuer that he has no conflict of interest that could
affect his ability to provide an unbiased valuation; and
NZ RegCo
2
ii. a statement from the independent valuer outlining his relevant qualifications and
expertise; and
d. NZ RegCo will publish the certificate alongside publication of the waiver decision.
Reasons – Rule 7.8.5(b)
6. The policy behind Rule 7.8.5(b) is to ensure that security holders being asked to vote on
resolutions to which Rule 7.8.5(b) apply, receive the benefit of an independent evaluation that
allows them to understand and scrutinise the merits of that transaction and highlight for
shareholders where Related Parties may be receiving an opportunity which shareholders,
generally, are not receiving.
7. In coming to the decision to provide the waiver from Rule 7.8.5(b) set out in paragraph 4 above,
NZ RegCo has considered that:
a. the policy is not offended where the purpose of the issue of the Consideration Shares is not
complicated or difficult for shareholders to understand;
b. the maximum number of Consideration Shares that may be issued is fixed at 1 million, giving
shareholders certainty as to what they are approving;
c. the issue price for the Consideration Shares is fixed at $0.50 which represented a premium to
the market price of shares when it was agreed. Further detail on this assessment is set out in
the Notice of Meeting. Shareholders can assess the financial implications and fairness of the
Consideration Shares with reference to this assessment;
d. the Notice of Meeting sets out sufficient information to enable shareholders to understand the
effect and consequences of the resolution;
e. PHL’s existing shareholders will be asked to consider the resolution to approve the issue of
Consideration Shares with the knowledge of the waiver sought having been granted;
f. the certification conditions in this waiver provide comfort that the Non-Interested Directors
consider that:
i. the Share issue is in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders;
ii. the Acquisition is in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders;
iii. the terms of the Acquisition have been entered into and negotiated on an arm’s length
commercial basis;
iv. PHL was not influenced enter into the Acquisition by the Related Party; and
v. the waivers are in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders; and
g. there is precedent for this decision.
Reasons – Rule 7.8.8(b)
8. The policy behind Rule 7.8.8(b) is to ensure that shareholders receive the benefit of an
independent evaluation that allows them to understand and scrutinise the merits of the transaction
where there is potential for undue influence by Related Party involvement.
9. In coming to the decision to provide the waiver from Rule 7.8.8(b) set out in paragraph 4 above,
NZ RegCo has considered that:
NZ RegCo
3
a. the Independent Valuation provides an independent, external, benchmark of the market value
of the Acquisition;
b. the outcome of the Independent Valuation together with the detail in the Notice of Meeting
provides PHL’s shareholders with information that allows the shareholders to objectively
assess the merits of the Acquisition to make an informed voting decision;
c. PHL submits, and NZ RegCo has no reason not to accept, that PHL has addressed (or
provided an equivalent for) the specific information requirements of Rule 7.10.2 through the
disclosure in the directors’ certificate and the disclosure on the Independent Valuation in the
Notice of Meeting. PHL submits there is a sufficient information to ensure shareholders can
make an informed decision;
d. entry into, and the terms of, the Acquisition were negotiated on an arm’s length basis and as a
condition of the waivers, the Non-Interested Directors will provide certification to this effect;
e. the Notice of Meeting sets out sufficient information to enable shareholders to assess the
merits and consequences of the Acquisition;
f. PHL’s existing shareholders will be asked to consider the resolution to approve the Acquisition
with the knowledge of the waiver sought having been granted; and
g. the certification conditions in this waiver provide comfort that the Non-Interested Directors
consider that:
i. the Share issue is in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders;
ii. the Acquisition is in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders;
iii. the terms of the Acquisition have been entered into and negotiated on an arm’s length
commercial basis;
iv. PHL was not influenced enter into the Acquisition by the Related Party; and
v. The waivers are in the best interests of, and fair and reasonable to, PHL and all non-
associated shareholders;
10. PHL has submitted and NZ RegCo has no reason not to accept that:
a. the Acquisition is appropriate in this context, as the Acquisition has clear strategic merit for
PHL. Since acquiring other aged care facilities, PHL’s core focus has been on lifting
occupancy at its facilities and realising operational efficiencies across its facilities to create a
strong foundation for further growth by acquisition;
b. the Purchase Price represents a $1.2 million (or a 4.58%) discount to the independently
determined current market value of Chatswood, and where the Non-Interested Directors have
certified that the terms are fair and reasonable, shareholders can opine on the fairness of the
Acquisition when considering the Notice of Meeting; and
c. a number of potential acquisitions have been considered by PHL and either disregarded
(particularly due to location, local market demographics or differing views on value) or remain
under investigation. The Non-Interested Directors certify that the Acquisition is in the best
interests of PHL and its non-associated shareholders given its strategic fit with PHL’s existing
portfolio.
NZ RegCo
4
Appendix One
1. Promisia Healthcare Limited (PHL) is a Listed Issuer with its ordinary shares quoted on the NZX
Main Board.
2. PHL operates in the aged care industry and currently operates five residential care facilities and
three retirement villages in three clusters across New Zealand. PHL has a strategy to grow by
undertaking acquisitions of operational retirement villages and aged care facilities.
3. As announced to market on 6 August 2026, PHL has entered into a conditional agreement to
acquire 100% of the shares in two companies, Chatswood Retirement Limited and Chatswood
Lifecare Limited (the Targets) which together own and operate the Chatswood residential care
facility (Chatswood) for total consideration of $25 million (Acquisition).
4. Chatswood is located at 60 Hawford Road, Opawa, Christchurch, within proximity to one of PHL’s
existing aged care facilities. Chatswood comprises of a purpose built and integrated high needs
aged care and retirement village complex spanning 1.2643 hectares. Chatswood is expected to
complement PHL’s existing offering in the region.
5. The Targets are owned in equal proportions by:
a. a family trust associated with Rhonda Sherriff, the Chair of PHL’s Board (Sherriff Interest)
who is a Related Party of PHL; and
b. a family trust associate with Reuben Ennor, (Ennor Interest).
6. The due diligence investigations and negotiations on the terms and conditions of the Acquisition
were conducted by a sub-committee comprising of Non-Interested Directors (excluding the
Related Party). That sub-committee commissioned the Independent Valuation to validate the
Purchase Price and assist the PHL Board in establishing the carrying value of Chatswood for
PHL’s financial statements. The Independent Valuation valued Chatswood at $26.2 million on 31
July 2026, $1.2 million above the Purchase Price. A letter setting out the valuation of the
Chatswood will accompany the Notice of Meeting.
7. The purchase price payable by PHL (Purchase Price) for the Acquisition consists of:
a. $24 million in cash, which will be funded utilising a new core facility and bridge facility with
Bank of New Zealand to the amount of $20 million, and PHL’s cash on hand;
b. an issue of up to 1 million fully paid ordinary shares in PHL (Shares) to the Sherriff Interest at
an issue price of $0.50 per Share (Consideration Shares) on the terms of a subscription
agreement which is summarised in the Notice of Meeting. Rhonda Sherriff does not currently
hold any Shares (either directly or through any Associated Person); and
c. an issue of a convertible note to the Ennor Interest with a face value of $500,000
(Convertible Note) on the terms of a convertible note agreement which is summarised in the
Notice of Meeting. The convertible note matures 12 months after 1 October 2026
(Completion Date) and may be converted into Shares at the option of the Ennor Interest at
any time following maturity at a conversion price of $0.50 per Share. To the extent not
converted, the principal will be repayable in full.
8. If approved by shareholders and the Acquisition becomes unconditional, settlement of the
Transaction will occur on the Completion Date.
Rule Requirements
9. PHL is seeking shareholder approval for the Acquisition under Rules 5.1.1(b) and 5.2.1, and the
issue of Consideration Shares and Convertible Note under Rule 4.2.1, respectively, at its 2026
NZ RegCo
5
Annual Meeting of Shareholders to be held on 27 August 2026. PHL released its notice of
meeting via the NZX Market Announcement Platform on 13 August 2026 (Notice of Meeting).
10. Under Rule 7.8.5(b), because more than 50% of the Consideration Shares are proposed to be
issued to the Sherriff Interest, an Associated Person of a director of PHL, the Notice of Meeting
must be accompanied by an Appraisal Report.
11. The Acquisition is a Material Transaction as the consideration payable by PHL is above 10% of
PHL’s Average Market Capitalisation. The Acquisition is a Material Transaction with a Related
Party under Rule 5.2.1, as Rhonda Sherriff is both associated with the vendor and a director of
PHL. Rule 7.8.8(b) is therefore triggered, and the Notice of Meeting must be accompanied by an
Appraisal Report.
12. PHL is therefore seeking waivers from Rules 7.8.5(b) and 7.8.8(b) to enable PHL to release its
Notice of Meeting without an accompanying Appraisal Report.
13. Further information on the Acquisition and the Consideration Shares can be found in the Notice of
Meeting.
NZ RegCo
6
Appendix Two
Rule 7.8.5
Rule 7.8.5 A notice of meeting to consider a resolution of the nature referred to in Rule 7.8.4
(other than a resolution to permit an issue under Rule 4.7.1) must be accompanied by
an Appraisal Report if:
(...)
(b) more than 50% of the Financial Products to be issued are intended or likely to be
acquired by Directors or Associated Persons of Directors, or
(...)
Rule 7.8.8
Rule 7.8.8 A notice of meeting for the purposes of Rule 5.2.1 must:
(a) be reviewed by NZX in accordance with Rule 7.1,
(b) be accompanied by an Appraisal Report, and
(c) contain such other material as is necessary to enable the holders of Financial
Products entitled to Vote to decide whether the transaction price and terms are
fair.
---
Promisia Healthcare Limited
(Company)
Non-interested Directors Certificate
(Condition of NZX RegCo’s waiver from NZX Listing Rule 7.8.5(b) and 7.8.8(b))
DATED
BACKGROUND
A. Capitalised terms not defined in this certificate shall have the meanings given to them in the
NZX Listing Rules (the Rules).
B. The Company proposes to purchase 100% of the shares in Chatswood Retirement Limited
and Chatswood Lifecare Limited (the Targets) for total consideration of $25 million
(Acquisition). Together, the Targets own and operate the Chatswood Retirement Village
(Facility).
C. A family trust associated with Rhonda Sherriff (the Sherriff Interest), the Chair of the
Company’s board, owns 50% of the shares in each of the Targets.
D. The purchase price payable by the Company (Purchase Price) to complete the Acquisition is:
a. $24 million in cash;
b. an issue of up to 1 million fully paid ordinary shares in the Company (Shares) at an issue
price of $0.50 per Share (Issue Price) to the Sherriff Interest (Share Issue); and
c. an issue of a convertible note to the other shareholder of the Targets (Noteholder) with
a face value of $500,000 and may be converted into Shares at the option of the
Noteholder at any time in the 12-month period following completion of the Acquisition at
a conversion price of $0.50 per Share.
E. Shareholder approval for the Acquisition and the Share Issue is being sought under Rules
5.1.1(b) and 5.2.1, and 4.2.1, respectively. The Company has on or about the date of this
certificate released a notice of meeting of shareholders setting out further particulars of the
Acquisition and the Share Issue, and the shareholder approvals sought (Notice).
F. In a decision of NZX Regulation Limited (NZ RegCo) dated on or around the date of this
certificate (the Decision), NZ RegCo granted the Company a waiver from Rule 7.8.5(b) and
7.8.8(b) to the extent required to allow the Company to enter into the Acquisition without
preparing an Appraisal Report to accompany the Notice (Waiver).
G. The Company applied for the waiver under Rule 7.8.5(b) because:
a. the Share Issue is overall a modest component of the Purchase Price;
b. Rhonda Sherriff will remain a director of the Company following completion of the
Acquisition and the Share Issue will align her interests with those of the Company’s
shareholders;
c. When the Issue Price was set it reflected a premium to the then market price of the
Company’s shares; and
d. the Company is providing shareholders with all material terms of the Share Issue in the
Notice,
Docusign Envelope ID: 606086E6-C74D-8A94-81F4-9D5222C95508
13 August 2026
therefore, an Appraisal Report was considered by the non-interested directors to have
limited value for shareholders given the simple nature of the Share Issue and that on the
information being provided shareholders can make a fully informed voting decision. The
costs of commissioning an appraisal report were therefore considered to outweigh the
benefits.
H. The Company applied for the waiver under Rule 7.8.8(b) because:
a. the Company commissioned an independent valuation of the Facility from CBRE. That
valuation values the Facility at a ~5% premium to the Purchase Price;
b. the non-interested directors are accordingly satisfied that as a result of the Acquisition
an inappropriate transfer of value to the Sherriff Interest is not occurring;
c. the Board’s decision making to pursue the Acquisition and approve the terms of the
Acquisition was undertaken completely independently of Rhonda Sheriff who did not
participate in any relevant Board deliberations or decisions,
therefore, the time and cost of preparing an Appraisal Report, in addition to the Independent
Valuation, was considered disproportionate to any benefit that shareholders may receive
from reviewing an Appraisal Report
I. The Waiver was given on the condition that the non-interested directors of the Company give
this certificate.
CERTIFICATION
We, the undersigned, being all of the directors of the Company who are not interested in the
Acquisition, certify that in our opinion:
1 The Share Issue is in the best interests of, and fair and reasonable to the Company and all
non-associated shareholders of the Company on the following grounds:
1.1 The cash component of the Purchase Price is being funded by new borrowings from
the Bank of New Zealand. The Share Issue allows the Company to fund a modest
proportion of the Purchase Price through equity and give it additional headroom in its
LVR covenant.
1.2 The Issue Price represented a premium to the market price of Shares at the time the
Issue Price was negotiated and agreed. At that time Shares were trading between
$0.42 and $0.46 per Share. The Issue Price remains consistent with the exercise
price for the Company’s quoted warrants (under the ticker code ‘PHLWA’).
1.3 as otherwise outlined in the background section above.
2 The Acquisition is in the best interests of, and fair and reasonable to the Company and all
non-associated shareholders of the Company on the following grounds:
2.1 The Acquisition is consistent with the Company’s growth strategy of growth via
acquiring facilities in regional clusters where operational efficiencies can be realised
and a known high degree of demand for aged care exists.
2.2 The Acquisition is entirely within the ordinary course of the Company’s business,
rather than being a transaction that changes, in any way, the essential nature of the
business.
2.3 The Acquisition will be immediately earnings accretive to the Company and the
Facility has future development potential that could further enhance earnings and the
market value of the Facility.
Docusign Envelope ID: 606086E6-C74D-8A94-81F4-9D5222C95508
2.4 The Purchase Price represents a $1.2 million (or a 4.58%) discount to the
independently determined current market value of the Facility and, despite being
largely funded by debt, will increase the net tangible assets of the Company.
2.5 as otherwise outlined in the background section above.
3 The terms of the Acquisition have been entered into, and negotiated, on an arm’s length
commercial basis, on the following grounds:
3.1 Rhonda Sherriff was not involved in any aspect of Promisia’s decision making in
relation to the Acquisition. In particular, Rhonda Sherriff was not involved in:
3.1.1 the Company’s assessment of the value of the Facility (including the
commissioning of an independent valuation by CBRE);
3.1.2 the Company’s legal, financial, or operational due diligence on the Targets or;
3.1.3 the Board’s consideration of the Acquisition or the negotiation of the sale and
purchase agreement; or
3.1.4 the Board’s decision to enter the sale and purchase agreement and proceed
with the Acquisition.
3.2 The Purchase Price was set by reference to a historic independent valuation of the
Facility (commissioned by the Vendors) and a current valuation (commissioned by the
Company) and dated as at 31 July 2026.
3.3 The Company undertook extensive legal, financial, and operational due diligence
investigations prior to entering into the Acquisition to verify the reasonableness of the
terms and conditions of the Acquisition and the Purchase Price.
3.4 Rhonda Sherriff obtained independent legal advice and negotiated with the Company
strictly in her capacity as a vendor.
3.5 The terms of the Acquisition are considered customary terms for a transaction of this
nature and do not include any novel or extraordinary terms indicating a non-
commercial arrangement.
4 The Company was not influenced to enter into the Acquisition by Rhonda Sherriff on the
following grounds:
4.1 As noted at paragraph 2.1, the Acquisition is consistent with the Company’s stated
growth strategy and will merely represent an expansion of its current ordinary course
of business operations in a locality where it already operates.
4.2 The Company’s due diligence investigations were undertaken exclusively by the
Company’s executive team and external legal advisors. The results of these
investigations were assessed by the non-interested directors.
4.3 Rhonda Sherriff was not involved in the Board’s decision to make an offer to acquire
the Facility, the Board’s consideration of due diligence findings or the Board’s
approval of the Acquisition or its terms.
4.4 The non-interested directors-initiated discussions for the Acquisition on behalf of the
Company based on their extensive industry experience and unanimous view that the
Facility was of a high quality.
5 The Waiver is in the best interests of, and fair and reasonable to, the Company and all non-
associated shareholders of the Company because:
Docusign Envelope ID: 606086E6-C74D-8A94-81F4-9D5222C95508
5.1 the information in the Notice is sufficient to enable equity security holders to make an
informed voting decision on the Acquisition and the Share Issue;
5.2 shareholders will have the opportunity to scrutinise the Acquisition at the Company’s
annual shareholder meeting;
5.3 the Share Issue and the Acquisition is in the best interests of the Company and all of
its shareholders for the reasons set out in paragraph 1 and 2 above;
5.4 the Company was not influenced by Rhonda Sherriff to enter into the transactions
but, rather, entered into the Acquisition after over 8 months of commercial and arms-
length negotiations, as set out in paragraphs 3 and 4 above;
5.5 therefore, the policy behind Rules 7.8.5(b) and 7.8.8(b) are not offended; and
5.6 the granting of the Waiver allows the Acquisition to proceed without incurring the
unnecessary cost of an Appraisal Report.
SIGNED
Tom Brankin, Director Tony Mortensen, Director
Craig Percy, Director Jill Hatchwell, Director
Docusign Envelope ID: 606086E6-C74D-8A94-81F4-9D5222C95508
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.